ARTICLE | Financial News
TCR2 seeks IPO as first program slated to enter clinic
December 28, 2018 10:56 PM UTC
Looking to bring at least one of its cell therapy programs to the clinic next year, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Friday to raise $100 million in an IPO on NASDAQ.
TCR2 is developing T cell receptor fusion constructs (TRuCs), which comprise tumor antigen recognition domains fused to TCRs. The company thinks its TRuCs could have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies (see "TRuCs vs. CARs")...
BCIQ Company Profiles